Human Genome Sciences, Inc. (Nasdaq: HGSI) and Aegera Therapeutics, Inc. announced that HGS has initiated dosing in a Phase 1 clinical trial to evaluate the safety and tolerability of its lead IAP inhibitor, HGS1029, as monotherapy in patients with advanced lymphoid tumors.
More...
iHav.net - Your Uncensored Offtopic Community
If this is your first visit, please click the Sign Up now button to begin the process of creating your account so you can begin posting on our forums! The Sign Up process will only take up about a minute of two of your time.
|
|
|
Results 1 to 1 of 1
-
11-24-2009, 01:31 PM #1Senior Member
- Join Date
- Mar 2008
- Posts
- 12,518
- Downloads
- 0
- Uploads
- 0
Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial O
Reply With QuoteSimilar Threads
-
Vicus Therapeutics Announces Initiation Of Phase 2 Trial To Evaluate VT-122 In Patien
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 12-28-2010, 02:00 PM -
GlaxoSmithKline And Human Genome Sciences Announce FDA Extension Of BenlystaŽ PDUFA T
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 12-04-2010, 02:00 PM -
GlaxoSmithKline And Human Genome Sciences Announce FDA Priority Review Designation Fo
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 08-21-2010, 01:00 PM -
Human Genome Sciences And Lonza Enter Commercial Manufacturing Agreement For BENLYSTA
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 07-15-2010, 01:00 PM -
Human Genome Sciences And Aegera Therapeutics Announce Initiation Of Clinical Trial O
By ! D33NA ! in forum Health and FitnessReplies: 0Last Post: 11-24-2009, 01:32 PM
Bookmarks